An observational study in Breast Edema, Breast Lymphedema and Lymphedema, Breast Cancer, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Massachusetts General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Breast Cancer Lymphedema with a site in United States — 8 open to participants now, 10 under way, 1 of them phase 3. Breast Cancer Lymphedema · United States.
Among the 15 studies in Breast Cancer Lymphedema with a site in United States, this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 14th registered.
124 studies on the registry are indexed under Breast Cancer Lymphedema; 39 are open to participants now.
Browse Breast Cancer Lymphedema studies →8 of the 15 studies in Breast Cancer Lymphedema with a site in United States are open now. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18–75 · Women only
University of Florida · Sites in United States
Ages 18–99
Texas Woman's University · Sites in United States
Ages 18+ · Women only
University Hospital, Basel, Switzerland · Sites in United States, Austria, Belgium and 12 more countries
Ages 18+
Stanford University · Sites in United States
Ages 18–75 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Breast Cancer Lymphedema studies recruiting now, 8 (33%) set no upper age limit and 9 (38%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 30 is below the median of 80 across 25 observational studies indexed under Breast Cancer Lymphedema.
Median enrollment 45 across the 12 interventional studies, 261 across the 3 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 15 have an industry lead sponsor. The 9 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 4 studies filed under Breast Cancer Lymphedema — fewer than ten, so there is no comparison to draw.
5 of the studies in Breast Cancer Lymphedema with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04241341Phase 3Memorial Sloan Kettering Cancer CenterDoes Immediate Lymphatic Reconstruction Decrease the Risk of Lymphedema After Axillary Lymph Node Dissection | 2027-01 |
| NCT05366699Stanford UniversityLYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy | 2027-06-01 |
| NCT05326165Massachusetts General HospitalEarly Intervention | 2027-06-30 |
| NCT05890677University Hospital, Basel, SwitzerlandThe LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema | 2027-09 |
| NCT05142800Massachusetts General HospitalScreening For BCRL In Targeted Therapy For Breast Cancer | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 15 studies in Breast Cancer Lymphedema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn if participants agree to take part in the study, if the methods we are using for the study are feasible for the participants and the researchers, and to study how well two tools (tissue dielectric constant and ultrasound) measure breast edema after breast conserving surgery for breast cancer.
Participants who agree to be in the study will be asked to come in for one appointment of approximately two hours. All data will be collected during this one visit. Participants will be asked to fill out two questionnaires regarding their symptoms, and one questionnaire regarding their surgical scar. The research staff will conduct a clinical examination, measure breast edema using ultrasound and tissue dielectric constant, measure arm volume with the perometer and fluid with the SOZO, and take photographs of both breasts.
The goal of this observational study is to learn if the study protocol is feasible, if we can accrue participants easily, and to determine how well two tools (tissue dielectric constant and ultrasound) identify breast edema after breast conserving surgery for breast cancer.
Participants will be asked to attend one appointment in which all data will be collected. This will include questionnaires regarding symptoms, clinical examination, measurement of breast edema using two tools (ultrasound and tissue dielectric constant), measurement with the perometer and SOZO, and clinical photographs.
Women screened for lymphedema in the MGH Lymphedema Research Program Prospective Screening Program; and/or women treated in physical or occupational therapy for breast cancer-related conditions after breast conserving surgery.
All participants must meet the following inclusion criteria:
EXCLUSION CRITERIA
Participants will be excluded if they:
Have any medical condition that may result in breast swelling;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will contain women who report breast edema and have been diagnosed with breast edema through clinical examination
These participants do not report a history of breast edema and do not have a history of breast edema.
Tissue Dielectric Constant
A TDC interbreast ratio ≥ 1.28 in any quadrant will be used as an indicator of breast lymphedema
Time frame: Baseline
Breast Ultrasound
Skin thickness \>1.60 mm in superior and lateral quadrants, \>2.0 mm in the medial and inferior quadrants will be used as an indicator of breast lymphedema.
Time frame: Baseline
Patient-Reported Outcome Measures
Breast Cancer Treatment Outcome Scale (BCTOS-12) Minimum Score = 12, Maximum Score = 48 Higher score indicates worse outcome
Time frame: Baseline
Patient-Reported Outcome Measures
Breast-Q Version 2.0 Breast Conserving Therapy Module, Postoperative Scales i. Psychosocial Well-Being (min score 10, max score 50), higher score indicating better outcome
Time frame: Baseline
Scar Assessment Tool
Patient and Observer Scar Scale Linear Scar Version 3.0
Time frame: Baseline
Clinical Examination of Lymphedema of the Upper Extremity Clinical Exam Tool
This is a validated measure used to administer clinical examination of the breast, trunk and upper extremity for lymphedema
Time frame: Baseline
Clinical Examination - Pitting Edema
The following will be assessed: * Each breast quadrant: Presence or absence of pitting edema * The participant is placed in supine. The examiner's thumb is placed firmly on the participant's skin, applying sustained pressure to the skin and superficial tissue for one minute. Upon release of the pressure, an indentation of the tissue at the test site is defined as pitting and is recorded as Yes in the relevant quadrant. If there is no change in the tissue, record No to pitting oedema.
Time frame: Baseline
Clinical Examination - Peau d'orange
The following will be assessed: * Each breast quadrant, lateral chest wall and inframammary tissues: Presence or absence of peau d'orange * The participant is positioned sitting. The examiner slightly compresses the breast tissue between their first finger and thumb to look for the orange peel appearance to the skin. A light can be shone tangentially across the breast to assist in identifying peau d'orange.
Time frame: Baseline
Clinical Examination - Tissue fibrosis
The following will be assessed: * Each breast quadrant: Presence or absence of tissue fibrosis * The participant is placed in supine. The examiner uses their first finger and thumb to palpate the tissue and gently pinch the tissue to assess for any tissue thickening, increased firmness or density and/or tissue retraction or fixation, compared to the equivalent tissue on the unaffected side. If the participant has had surgery on the unaffected breast (e.g. breast reduction), the tissue in the quadrant most distal to the incision site is used as the comparator tissue. N/A is marked in the table for the unaffected breast, unless the participant has had surgery on the unaffected side and tissue fibrosis is detected as a result compared to other quadrants of the unaffected breast.
Time frame: Baseline
Clinical Examination - Tenderness to palpation
The following will be assessed: * Each breast quadrant: Presence or absence of tenderness to palpation. * The examiner will lightly palpate the tissue of each breast quadrant to see if the participant reports any pain or tenderness. Deep palpation, particularly medially in the breast, may cause tenderness in the costochondral cartilages.
Time frame: Baseline
Clinical Examination - Erythema
The following will be assessed: \- Each breast quadrant: Presence or absence of erythema (redness of the skin)
Time frame: Baseline
Clinical Examination - Scar localization
The following will be assessed: \- Scar measurements for the breast and axillary scars, including location (quadrant, distance from the center of the nipple to the center of the scar), scar length, width and orientation (vertical, horizontal, oblique or radial).
Time frame: Baseline
Clinical Examination - Visual fullness
The following will be assessed: \- Lateral chest wall and inframammary tissue: The examiner will record presence or absence of visual fullness
Time frame: Baseline
Clinical Examination - Stemmer sign
The following will be assessed: \- Lateral chest wall and inframammary tissue: Presence or absence of the Stemmer sign. The Stemmer sign is a physical examination finding used to diagnose lymphedema. If the examiner cannot pinch the skin then this positive finding is associated with lymphedema. The Stemmer sign has been found to be a sensitive predictor for primary and secondary lymphedema with moderate specificity (Goss JA, Greene AK. Sensitivity and Specificity of the Stemmer Sign for Lymphedema: A Clinical Lymphoscintigraphic Study. Plast Reconstr Surg Glob Open. 2019 Jun 25;7(6):e2295. doi: 10.1097/GOX.0000000000002295. PMID: 31624689; PMCID: PMC6635205)
Time frame: Baseline
Clinical Examination - Tissue thickening
The following will be assessed by the examiner: \- Nipple and nipple-areolar complex: Tissue thickening on the side of surgery as compared to the unaffected side
Time frame: Baseline
Clinical Examination - Skin color changes
The following will be assessed by the examiner: \- Nipple and nipple-areolar complex: Skin color changes as compared to the unaffected side (lighter, darker, same)
Time frame: Baseline
Patient-Reported Outcome Measures
Breast-Q Version 2.0 Breast Conserving Therapy Module, Postoperative Scales ii. Sexual Well-Being (min score 6, max score 30), higher score indicating better outcome
Time frame: Baseline
Patient-Reported Outcome Measures
Breast-Q Version 2.0 Breast Conserving Therapy Module, Postoperative Scales iii. Satisfaction with Breasts (min score 11, max score 44), higher score indicating better outcome
Time frame: Baseline
Patient-Reported Outcome Measures
Breast-Q Version 2.0 Breast Conserving Therapy Module, Postoperative Scales iv. Physical Well-Being: Chest (min score 10, max score 30), higher score indicating better outcome
Time frame: Baseline
Patient-Reported Outcome Measures
Breast-Q Version 2.0 Breast Conserving Therapy Module, Postoperative Scales v. Adverse Effects of Radiation (min score 6, max score 18), higher score indicating better outcome
Time frame: Baseline
Patient-Reported Outcome Measures
Breast-Q Version 2.0 Breast Conserving Therapy Module, Postoperative Scales vi. Satisfaction with Information - Breast Surgeon (min score 12, max score 48), higher score indicating better outcome
Time frame: Baseline
Perometry
Perometry will be undertaken per clinical protocol to screen for arm lymphedema
Time frame: Baseline
Bioimpedance Spectroscopy (SOZO)
Bioimpedance Spectroscopy will be undertaken per clinical protocol
Time frame: Baseline
Clinical Photographs
Clinical photographs of each breast, repeated for the right and then the left breast, taken per study protocol 5 positions each side, including a close up photo of the breast and surgical scar.
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2025 to primary completion in Feb 2026, 9 months.
Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Feb 2026, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →